(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 19.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.68%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.94%.
Vericel's revenue in 2025 is $249,119,000.On average, 3 Wall Street analysts forecast VCEL's revenue for 2025 to be $13,886,143,814, with the lowest VCEL revenue forecast at $13,867,978,140, and the highest VCEL revenue forecast at $13,908,850,906. On average, 3 Wall Street analysts forecast VCEL's revenue for 2026 to be $17,239,375,817, with the lowest VCEL revenue forecast at $16,866,323,521, and the highest VCEL revenue forecast at $17,689,834,067.
In 2027, VCEL is forecast to generate $21,463,046,356 in revenue, with the lowest revenue forecast at $20,149,769,061 and the highest revenue forecast at $22,225,197,292.